You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. TruEnamel: A dental product that treats, protects, desensitizes and whitens teeth

    SBC: TruEnamel, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Dentin hypersensitivity is a painful condition affecting from of the population It is caused by the movement of fluid in the dentinal tubules and can be eliminated by occluding these patent tubules Tooth whitening is a $ billion business in America and is predicted to grow both here and abroad In this grant we propose a treatment for dentin hypers ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. A Low Cost, Quantitative, Chemical Specific Device for Illicit Drug Detection

    SBC: MKS Technology            Topic: NIDA

    DESCRIPTION provided by applicant This proposal will assess the quantitative capabilities of surface enhanced Raman scattering SERS detection of cocaine and marijuana metabolites in urine samples Combining low cost instrumentation and novel chemical sensing provides an innovative new approach for diagnosing illicit drug use Current methods use a colorimetric indicator to screen specimens fo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Advanced Nitric Oxide Release Bactericidal Urinary Catheters

    SBC: BIOCREDE INC.            Topic: 300

    DESCRIPTION provided by applicant In Phase I Biocrede developed a completely new urinary tract silicone Foley catheter with a andgt month shelf life made from a proprietary polymeric formulation to effectively reduce catheter associated urinary tract infections CAUTI via nitric oxide NO release for andgt weeks Key features of the new technology include catheters continuously d ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Reduced gluten cereal grains

    SBC: Arcadia Biosciences, Inc.            Topic: 300

    DESCRIPTION provided by applicant Celiac disease CD is the most common food sensitive enteropathy known affecting approximately of the population and its incidence appears to be on the rise In addition non celiac gluten sensitivity GS has recently been revealed to be a distinct condition that affects a growing number of individuals Both of these conditions are triggered by gluten a ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. PDE4B Inhibitors for Treating Brain Injury

    SBC: Tetra Discovery Partners, Inc.            Topic: 106

    DESCRIPTION provided by applicant This proposal will develop a new small molecule drug to be advanced into human clinical trials in the chronic post TBI patient who still has chronic cognitive impairments months to years after the initial TBI According to the Centers for Disease Control approximately million Americans suffer from post TBI cognitive impairments This includes people sustai ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Validation and Cryopreservation of Ligament Engineered from Human Bone Marrow

    SBC: STEL Technologies, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant The founders of Skeletal Tissue Engineering Laboratory Technologies LLC STEL are researchers at the University of Michigan Our research team has developed an innovative and paradigm shifting approach to ligament tissue engineering and a unique methodology for ACL replacement This tissue engineered ligament technology offers the possibility of radical impr ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. S-Nitrosothiol-Based Rinse/Aerosol Solutions For Treatment/Prevention of Rhinosinusitis

    SBC: NOTA Laboratories LLC            Topic: NIAID

    DESCRIPTION provided by applicant The purpose of the research being proposed is to develop a highly effective nasal rinse that can treat chronic rhinosinusitis CRS in an entirely new way Often CRS is overlooked because it is rarely life threatening CRS is estimated to affect an astounding of the US population with direct costs exceeding $ billion annually and additionally causing ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Synactix Pharmaceuticals I-Corps Application

    SBC: SYNACTIX PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Polypharmacology represents a new and attractive approach to treat malignances as lasting and robust efficacy could be obtained through the inhibition of multiple survival pathways with one therapeutic agent In line with this method we have designed a RET rearranged during transfection VEGFR vascular endothelial growth factor receptor small molecule ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers.

    SBC: PROMUTECH PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Pathological activating mutations in the FLT kinase represent the most common genetic alteration in patients with acute myeloid leukemia AML occurring in approximately one third of cases Recently we performed translational studies that identified drug resistant kinase domain mutations in FLT ITD at the time of relapse in AML patients treated with the FLT ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Extraction and Characterization of a Safer, Cost-effective Anti-inflammatory

    SBC: Botanisol LLC            Topic: R

    DESCRIPTION provided by applicant Inflammatory disease states are leading causes of death and disability and a major cost to healthcare in the United States There is an epidemic of death and hospitalizations due to adverse effects from NSAIDs TAI LCx Turmeric Anti Inflammatory Lipophilic Component X is a novel anti inflammatory discovered in previously unrecognized pharmacologically activ ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government